1 / 63

Structures and Functions of the Respiratory System

Structures and Functions of the Respiratory System. Gas Exchange. Ventilation Diffusion (alveolar-capillary membrane) Perfusion Diffusion (capillary-cellular level). Ventilation Movement of Chest Wall. Ventilation. Depends on volume and pressure changes within thoracic cavity

rana-vance
Download Presentation

Structures and Functions of the Respiratory System

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Structures and Functions of the Respiratory System

  2. Gas Exchange Ventilation Diffusion (alveolar-capillary membrane) Perfusion Diffusion (capillary-cellular level)

  3. Ventilation Movement of Chest Wall

  4. Ventilation • Depends on volume and pressure changes within thoracic cavity • Diaphragm is major muscle of inspiration; also external intercostal muscles. Contraction increases diameter of thoracic cavity→ ↓ intrathoracic pressure →air flows into respiratory system • Expiration is passive process d/t lung elasticity. ↑ intrathoracic pressure→ air flows out of lungs • Accessory muscles

  5. Control of Ventilation Neural control- respiratory center in medulla & pons Central chemoreceptors – sensitive to pH Peripheral chemoreceptors- sensitive to paO2 Patients with COPD- hypoxic drive WOB- amount of effort required for the maintenance of a given level of ventilation (as WOB ↑s, more energy is expended for adequate ventilation)

  6. Factors Influencing Ventilation • Airway resistance- opposition to gas flow • Compliance- distensibility / stretchability - Dependent on lung elasticity & elastic recoil of chest wall - Decreased compliance- lungs difficult to inflate - Increased compliance- destruction of alveolar walls & loss of tissue elasticity

  7. DiffusionAlveolar-Capillary Membrane

  8. Oxyhemoglobin Curve

  9. Ventilation-Perfusion • Adequate diffusion depends on balanced ventilation-perfusion (V/Q) ratio • Normal lung: V=4L/min; Q= 5L/min (0.8) • If imbalanced: gas exchange interrupted - High V/Q= “wasted” or dead-space ventilation - Low V/Q= blood “shunted” past area; no gas exchange occurs

  10. V/Q Matching

  11. Perfusion

  12. DiffusionBody Tissue-Blood Capillary

  13. COPD • Progressive, irreversible airflow limitation • Associated with abnormal inflammatory response of lungs to noxious particles or gases

  14. COPDEtiology Cigarette smoking Occupational chemicals and dusts Air pollution Infection Heredity- A1-antitrysin deficiency Aging

  15. COPDPathophysiology Primary process is inflammation Inhalation of noxious particles→ inflammatory cells release mediators (leukotrienes, interleukins, TNF) → airways become inflammed with increased goblet cells → excess mucus production (bronchitis) & structural remodeling to peripheral airways with ↑d collagen & scar tissue

  16. COPDPathophysiology Destruction of lung tissue caused by imbalance of proteinases/antiproteinases results in emphysema with loss of attachments & peripheral airway collapse (Centrilobar- affects respiratory bronchioles/upper lobes/mild disease; panlobar- alveolar ducts, sacs, respiratory bronchioles- lower lobes/AAT deficiency

  17. COPDPathophysiology Air goes into lungs easily but unable to come out; air trapped in distal alveoli, causing hyperinflation & overdistension PV thickens with ↓surface area for gas exchange- V/Q mismatch

  18. COPD:Chronic Bronchitis vs. Emphysema

  19. Emphysema

  20. Chronic BronchitisBlue Bloater versus Pink Puffer

  21. COPDBehaviors • Develop slowly around 50 years of age after history of smoking • Cough, sputum production, dyspnea • In late stages, dyspnea at rest • Wheezing/chest tightness- may vary • Prolonged I:E, ↓BS, tripod position, pursed-lip breathing, edema • ↑ A-P diameter of chest • Advanced- weight loss, anorexia (hypermetabolic state) • Hypoxemia, possible hypercapnia • Bluish-red color from polycythemia, cyanosis

  22. Increased A-P DiameterBarrel-Chest

  23. COPDDiagnosis PFTs (↑ RV, ↓FEV1) CXR ABGs Sputum C&S if infection suspected EKG- RV hypertrophy 6 minute oxy-walk

  24. COPD – Classification

  25. COPDComplications Cor pulmonale- RV hypertrophy 2º pulmonary hypertension (late) Exacerbations of COPD Acute respiratory failure Peptic ulcer and gastroesophageal reflux disease Depression/anxiety

  26. COPD- Collaborative Care Smoking cessation Medications- bronchodilators (inhaled & step-wise), Spriva (LA anticholinergic), ICS Oxygen therapy RT- PLB, diphragmatic, cough, CPT, nebulization therapy Nutrition- Avoid over/underweight, rest 30” before eating, 6 small meals, avoid foods that need a great deal of chewing, avoid exercise 1 hr before meal, take fluids between meals to avoid stomach distension

  27. COPDNursing Diagnoses Ineffective Breathing Pattern Impaired Gas Exchange Ineffective Airway Clearance Imbalanced Nutrition: Less than Body Requirements

  28. Asthma • Chronic inflammatory disorder associated with airway hyperresponsiveness leading to recurrent episodes (attacks) • Often reversible airflow limitation • Prevalence increasing in many countries, especially in children

  29. AsthmaPathophysiology Airway hyperresponsiveness as a result of inflammatory process Airflow limitation leads to hyperventilation Decreased perfusion & ventilation of alveoli leads to V/Q mismatch Untreated inflammation can lead to LT damage that is irreversible Chronic inflammation results in airway remodeling

  30. AsthmaPotential Triggers Allergens – 40% Exercise (EIA) Air pollutants Occupational factors Respiratory infections – viral Chronic sinus and nose problems Drugs and food additives – ASA, NSAIDs, ß-blockers, ACEi, dye, sulfiting agents Gastroesophageal reflux disease (GERD) Psychological factors- stress

  31. Asthma Inflammation – Effects Bronchospasm Plasma exudation Mucus secretion AHR Structural changes

  32. Asthma InflammationClinical Manifestations Cough Chest tightness Wheeze Dyspnea Expiration prolonged -1:3 or 1:4, due to bronchospasm, edema, and mucus Feeling of suffocation- upright or slightly bent forward using accessory muscles Behaviors of hypoxemia- restlessness, anxiety, ↑HR & BP, PP

  33. AsthmaDiagnosis • History and patterns of symptoms • Measurements of lung function • PFTs- usually WNL between attacks; ↓ FVC, FEV1 • PEFR- correlates with FEV • Measurement of airway responsiveness • CXR • ABGs • Allergy testing (skin, IgE)

  34. AsthmaTherapeutic Goals • No (or minimal)* daytime symptoms • No limitations of activity • No nocturnal symptoms • No (or minimal) need for rescue medication • Avoid adverse effects from asthma medications • Normal lung function • No exacerbation • Prevent asthma mortality • * Minimal = twice or less per week

  35. AsthmaCollaborative Management Suppress inflammation Reverse inflammation Treat bronchoconstriction Stop exposure to risk factors that sensitized the airway

  36. AsthmaMedications • AntiinflammatoryAgents • Corticosteroids- suppress inflammatory response. Reduce bronchial hyperresponsiveness & mucus production, ↑ B2 receptors • Inhaled – preferred route to minimize systemic side effects • Teaching • Monitor for oral candidiasis • Systemic – many systemic effects – monitor blood glucose • Mast cell stabilizers- NSAID ; inhibit release of mediators from mast cells & suppress other inflammatory cells (Intal, Tilade)

  37. AsthmaMedications • Antiinflammatory Agents • Leukotriene modifiers • Block action of leukotrienes • Accolate, Singulair, Zyflo) • Not for acute asthma attacks • Monclonal Ab to IgE • ↓ circulating IgE • Prevents IgE from attaching to mast cells, thus preventing the release of chemical mediators • For asthma not controlled by corticosteroids • Xolair SQ

  38. AsthmaMedications • Bronchodilators • B-agonists- SA for acute bronchospasm & to prevent exercised induced asthma (EIA) (Proventil, Alupent); LA for LT control • Combination ICS + LA B-agonist (Advair) • Methylxanthines- Theophylline: alternative bronchodilator if other agents ineffective. Narrow margin of safety & high incidence of interaction with other medications • Anticholinergics- block bronchoconstriction . Additive effect with B-agonists (Atrovent)

  39. AsthmaPatient Teaching- Medications • Name/dosage/route/schedule/purpose/SE • Majority administered by inhalation (MDI, DPI, nebulizers) • Spacer + MDI- for poor coordination • Care of MDI- rinse with warm H2O 2x/week • Potential for overuse • Poor adherence with asthma therapy is challenge for LT management • Avoid OTC medications

  40. AsthmaCollaborative Care • GINA- decrease asthma morbidity/mortality & improve the management of asthma worldwide • Education is cornerstone • Mild Intermittent/Persistent: avoid triggers, premedicate before exercise, SA or LA Beta agonists, ICS, leukotriene blockers • Acute episode: Oxygen to keep O2Sat>90%, ABGs, MDI B-agonist; if severe- anticholinergic nebulized w/B agonist, systemic corticosteroids

  41. AsthmaNursing Diagnoses Ineffective Airway Clearance Impaired Gas Exchange Anxiety Deficient Knowledge

  42. Pneumonia HAP- pneumonia occurring 48 hours or longer after admission VAP- pneumonia occurring 48-72 hours after ET intubation HCAP- hospitalized for 2 or more days within 90 days of infection; resided in LTC facility; received IV therapy or wound care within past 30 days of current infection; attended a hospital or dialysis clinic Aspiration pneumonia- abnormal entry of secretions into lower airway

  43. PneumoniaPathophysiology • Congestion • Fluid enters alveoli; organisms multiply & infection spreads • Red hapatization • Massive capillary vasodilation; alveoli filled with organisms, neutrophils, RBCs, & fibrin • Gray hepatization • Blood flow decreases & leukocytes & fibrin consolidate in affected part • Resolution • Resolution & healing; exudate processed by macrophages

  44. PneumoniaRisk Factors • Aging • Air pollution • Altered LOC • Altered oral normal flora secondary to antibiotics • Prolonged immobility • Chronic diseases • Debilitating illness • Immunocompromised state • Inhalation or aspiration of noxious substances • NG tube feedings • Malnutrition • Resident of Long-term care • Smoking • Tracheal intubation • Upper respiratory tract infection

  45. Pneumonia Behaviors Usually sudden onset Fever, shaking chills, SOB, cough w/purulent sputum, pleuritic CP Elderly/debilitated- confusion or stupor

  46. Pneumonia- Complications Pleuritis Pleural effusion- 40% of hospitalized patients Atelectasis Bacteremia Lung abscess Empyema Pericarditis

More Related